48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast

 

48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast. A. Mammographic magnification view shows grouped calcifications in left breast (circle). Stereotactic biopsy yielded grade 2 DCIS. Patient underwent lumpectomy with tumor-negative surgical margins and radiation therapy. B. Mammographic magnification view obtained 4 years after diagnosis shows new calcifications at surgical site (circle). Stereotactic biopsy was performed, which revealed recurrent grade 2 DCIS. Patient then underwent mastectomy.


December 26, 2023 — Results published in the American Journal of Roentgenology (AJR) support mammographic surveillance protocol for patients with a previous breast cancer diagnosis of returning immediately to digital breast tomosynthesis (DBT) screening.

“Although the abnormal interpretation rate (AIR) was higher during the year after diagnosis compared to subsequent years, the AIR remained acceptably low (< 10%) in all years,” concluded lead investigator Dan Do, BA, from Massachusetts General Hospital in Boston.  

This AJR accepted manuscript included 8,090 patients (mean age, 65 years) with a prior breast cancer diagnosis who underwent 30,812 screening DBT examinations during Do et al.’s study period. The cancer detection rate (CDR) was 8.6 per 1,000 examinations, AIR was 5.7%, PPV 1 was 15.1%, sensitivity was 80.3%, specificity was 95.1%, and false-negative rate was 2.1%.

Ultimately, CDR showed a significant independent positive association with years since breast cancer diagnosis (adjusted OR 1.03, 95% CI 1.01-1.05, p<.001). Meanwhile, AIR evidenced significant independent negative association with years since breast cancer diagnosis (adjusted OR 0.99, 95% CI 0.98-1.00, p=.01)—being highest less than or equal to 1 year after diagnosis (7.5%) and lowest greater than 5, but less than 6 years postdiagnosis (5.0%).

For more information: www.arrs.org


Related Content

News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
News | Ultrasound Imaging

February 15, 2024 — According to the American Journal of Roentgenology (AJR), 10 abdominal radiologists showed ...

Time February 15, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
News | Breast Imaging

February 9, 2024 — An innovative breast imaging technique provides high sensitivity for detecting cancer while ...

Time February 09, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
Subscribe Now